Drugs / volamcabtagene durzigedleucel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04502446 | Jul 2020 → Aug 2024 | T-cell non-Hodgkin lymphoma | CRISPR Therapeutics AG | Terminated | No outcome recorded |
| Phase 1 | NCT04438083 | Jun 2020 → Oct 2024 | renal cell carcinoma | CRISPR Therapeutics AG | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | CRISPR Therapeutics | Results CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting crisprtx.com ↗
This first-in-human clinical trial exploring CD70-targeting CAR-T cell therapy in clear cell RCC (ccRCC) showed a tolerable safety profile with no off-target toxicities and encouraging antitumor activity. |
| 2022-09-28 | CRISPR Therapeutics | Regulatory CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL) crisprtx.com ↗
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL) |
| 2022-06-11 | CRISPR Therapeutics | Results CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress crisprtx.com ↗ |
| 2021-04-10 | CRISPR Therapeutics | Results CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function crisprtx.com ↗
The data demonstrated that CD70 knockout performed better than other checkpoint genes and provided advantages for CAR-T cells targeting multiple antigens beyond CD70. |
All press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | volamcabtagene durzigedleucel | “This study assesses the safety and activity of CTX130 (volamcabtagene durzigedleucel), a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured...” PMID 39617017 ↗ Nov 2024 |
| Known as | CTX130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04502446 ↗ |
| Known as | Volamcabtagen durzigedleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095158 ↗ |
| Modality | Cell therapy | “CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.” NCT04438083 ↗ |
| Route | Intravenous | “Administered by IV infusion following lymphodepleting chemotherapy.” NCT04438083 ↗ |
| Target | CD70 | “CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.” NCT04438083 ↗ |